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The authors would like to make the following adjustment to the above mentioned article. The Acknowledgments section should be changed to:
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The summary slide should be changed to:Landiolol, an ultra-short-acting β-blocker, is rapidly metabolized to inactive forms in the blood and liver, resulting in a short half-life of approximately 4 min in human blood. In addition, it selectively binds to β1 receptors, with a β1 receptor selectivity (β1/β2) as high as 251.The J-Land study was designed as a central registration, prospective, multicenter, single-blind, randomized, parallel-group study to evaluate the efficacy and safety of intravenous landiolol for achieving rapid control of tachycardia in patients with atrial fibrillation (AF)/atrial flutter (AFL) and left ventricular (LV) dysfunction. The primary efficacy endpoint was the percentage of patients with both a heart rate (HR) \<110 beats/min (bpm) and ≥20 % decrease from baseline at 2 h after administration.Two hundred patients with AF/AFL, HR ≥120 bpm, and LV ejection fraction (LVEF) 25--50 % were randomized to receive either landiolol (*n* = 93) or digoxin (*n* = 107).This subgroup analysis of the J-Land study indicated that landiolol was more useful, regardless of patient characteristics, as compared with digoxin in AF/AFL patients complicated with LV dysfunction. Particularly, in patients with impaired renal function, landiolol should be preferred for the purpose of acute rate control of AF/AFL tachycardia.

The online version of the original article can be found under doi:10.1007/s12325-014-0111-2.
